Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
Lancet Psychiatry
.
2019 Dec;6(12):977-979.
doi: 10.1016/S2215-0366(19)30394-3.
Epub 2019 Nov 1.
Author
Erick H Turner
1
Affiliation
1
Behavioral Health and Neurosciences Division, Portland Veterans Affairs Medical Center, Portland, OR 97239, USA; Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA. Electronic address: turnere@ohsu.edu.
PMID:
31680014
DOI:
10.1016/S2215-0366(19)30394-3
No abstract available
MeSH terms
Clinical Trials as Topic*
Depressive Disorder, Treatment-Resistant / drug therapy*
Humans
Ketamine / therapeutic use*
Treatment Outcome*
United States
United States Food and Drug Administration / standards*
Substances
Esketamine
Ketamine